On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease

Immunological Reviews

Volumn 169, Issue , 1999, Pages 175-194

  Kollias, George ^a   Douni, Eleni ^a   Kassiotis, George ^a   Kontoyiannis, Dimitris ^a  

^a HELLENIC PASTEUR INSTITUTE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; ENTERITIS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; KNOCKOUT GENE; MOUSE; MULTIPLE ORGAN FAILURE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; TISSUE INJURY; TRANSGENIC ANIMAL;

ANIMALS; ARTHRITIS, RHEUMATOID; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATORY BOWEL DISEASES; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MULTIPLE ORGAN FAILURE; MULTIPLE SCLEROSIS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032813516     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1999.tb01315.x     Document Type: Review

References (211)

1. 1. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992:10:411-452.
2. 2. Vandenabeele P, Declercq W, Beyaert R, Fiers W. Two tumor necrosis factor receptors; structure and function. Trends Cell Biol 1995;5:392-399.
3. 3. Grell M, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995;83:793-802.
4. 4. Higuchi Y, et al. Expression of a tumor necrosis factor α transgene in murine pancreatic β cells results in severe and permanent insulitis without evolution towards diabetes. J Exp Med 1992,176:1719-1731.
5. 5. Picarella DE, Kratz A, Li CB, Ruddle NH, Flavell RA. Transgenic tumor necrosis factor (TNF)-α production in pancreatic islets leads to insulitis, not diabetes. Distinct patterns of inflammation inTNF-α and TNF-β transgenic mice. J Immunol 1993;150:4136-4150.
6. 6. Probert L, et al. Wasting, ischemia, and lymphoid abnormalities in mice expressing T cell-targeted human tumor necrosis factor transgenes. J Immunol 1993;151;1894-1906.
7. 7. Keffer J, et al. Transgenic mice expressing human tumour necrosis factor; a predictive genetic model of arthritis. EMBO J 1991;10:4025-4031.
8. 8. Probert L, Akassoglou K, Pasparakis M, Kontogeorgos G, Kollias G. Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor α. Proc Natl Acad Sci USA 1995;92:11294-11298.
9. 9. Akassoglou K, Probert L, Kontogeorgos G, Kollias G. Astrocyte-specific but not neuron-specific: transmembrane TNF triggers inflammation and degeneration in the central nervous system of transgenic mice. J Immunol 1997;158:438-445.
10. 10. Akassoglou K, et al. Oligodendrocyte apoptosis and primary demyelination induced by local TNF/pSSTNF receptor signaling in the central nervous system of transgenic mice: models for multiple sclerosis with primary oligodendrogliopathy. Am J Pathol 1998;153:801-813.
11. 11. Kontoyiannis D, Pasparakis M, Pizarro T, Cominelli F, Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999:10:387-398.
12. 12. Ehl S, et al. Viral and bacterial infections interfere with peripheral tolerance induction and activate CD8' T cells to cause immunopathology. J Exp Med 1998;187:763-774.
13. 13. Grewal IS, Grewal KD, Wong FS, Picarella DE, Janeway CA Jr, Flavell RA. Local expression of transgene encoded TNF α in islets prevents autoimmune diabetes in nonobese diabetic (NOD) mice by preventing the development of auto-reactive islet-specific T cells. J Exp Med 1996;184:1963-1974.
14. 14. Satoh J, et al. Recombinant human tumor necrosis factor α suppresses autoimmune diabetes in nonobese diabetic mice. J Clin Invest 1989;84:1345-1348.
15. 15. Jacob CO, McDevitt HO. Tumour necrosis factor-α in murine autoimmune 'lupus' nephritis. Nature 1988;331:356-358.
16. 16. Green EA, Eynon EE, Flavell RA. Local expression of TNF-α in neonatal NOD mice promotes diabetes by enhancing presentation of islet antigens. Immunity 1995;9:733-743.
17. 17. Cope A, Ettinger R, McDevitt H. The role of TNF α and related cytokines in the development and function of the antoreactive T-cell repertoire. Res Immunol 1997;148:307-312.
18. 18. Benoist C, Mathis D. Cell death mediators in autoimmune diabetes - no shortage of suspects. Cell 1997;89:1-3.
19. 19. Piguet PF, Vesin C, Guo J, Donati Y, Barazzone C. TNF induced enterocyte apoptosis in mice is mediated by the TNF receptor 1 and does not require p53. Eur J Immunol 1998;28:3499-3505.
20. 20. Robbins DS, Shirazi Y, Drysdale BE, Lieberman A, Shin HS, Shin ML. Production of cytotoxic factor for oligodendrocytes by stimulated astrocytes. J Immunol 1987;139:2593-2597.
21. 21. Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988;23:339-346.
22. 22. Pasparakis M, Alexopoulou L, Episkopou V, Kollias G. Immune and inflammatory responses in TNF α-deficient mice: a critical requirement for TNF α in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response, J Exp Med 1996;184:1397-1411.
23. 23. Le Hir M, et al. Differentiation of follicular dendritic cells and full antibody responses require tumor necrosis factor receptor-1 signaling. J Exp Med 1996;183:2367-2372.
24. 24. Ranges GE, Zlotnik A, Espevik T, Dinarello CA, Cerami A, Palladino MAJ. Tumor necrosis factor α/cachectin is a growth factor for thymocytes. Synergistic interactions with other cytokines. J Exp Med 1988;167:1472-1478.
25. 25. Tartaglia LA, et al. Stimulation of human T-cell proliferation by specific activation of the 7S-kDa tumor necrosis factor receptor. J Immunol 1993;151:4637-4641.
26. 26. Lahn M, et al. Early preferential stimulation of γδ T cells by TNF α. J Immunol 1998;160:5221-5230.
27. 27. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-252.
28. 28. Cope AP, et al. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med 1997;185:1573-1584.
29. 29. Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 1995;377:348-351.
30. 30. Speiser DE, et al. Tumor necrosis factor receptor p55 mediates deletion of peripheral cytotoxic T lymphocytes in vivo. Eur J Immunol 1996;26:3055-3060.
31. 31. Herbein G, et al. Apoptosis of CD8 + T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4. Nature 1998;395:189-194.
32. 31. Collart MA, Baeuerle P, Vassalli P. Regulation of tumor necrosis factor α transcription in macrophages: involvement of four κ Β like motifs and of constitutive and inducible forms of NF-κ Β. Mol Cell Biol 1990;10:1498-1506.
33. 33. Yang Y, Chang JF, Parnes JR, Fathman CG. T cell receptor (TCR) engagement leads to activation-induced splicing of tumor necrosis factor (TNF) nuclear pre-mRNA. J Exp Med 1998;188:247-254.
34. 34. Beutler B, Krochin N, Milsark IW, Luedke C, Cerami A. Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science 1986;232:977-980.
35. 35. Goldfeld AE, Strominger JL, Doyle C. Human tumor necrosis factor α gene regulation in phorbol ester stimulated T and B cell lines. J Exp Med 1991;174:73-81.
36. 36. Sullivan KE, Wooten C, Schmeckpeper BJ, Goldman D, Petri MA. A promoter polymorphism of tumor necrosis factor α associated with systemic lupus erythematosus in African-Americans. Arthritis Rheum 1997;40:2207-2211.
37. 37. Kaijzel EL, et al. Functional analysis of a human tumor necrosis factor α (TNF-α) promoter polymorphism related to joint damage in rheumatoid arthritis. Mol Med 1998;4:724-733.
38. 38. Middleton PG, Taylor PR, Jackson G, Proctor SJ, Dickinson AM. Cytokine gene polymorphisms associating with severe acute graft-versus-host disease in HLA -identical sibling transplants. Blood 1998:92:3943-3948.
39. 39. Park KS, Mok JW, Rho SA, Kim JC. Analysis of TNFB and TNFA Ncol RFLP in colorectal cancer. Mol Cells 1998;8:246-249.
40. 40. McGuire W, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski D. Variation in the TNF-α promoter region associated with susceptibility to cerebral malaria. Nature 1994;371:508-510.
41. 41. Fernandez-Real JM, et al. The TNF-α gene Nco I polymorphism influences the relationship among insulin resistance, percent body fat, and increased serum leptin levels. Diabetes 1997;46:1468-1472.
42. 42. Stuber F, Petersen M, Bokelmann F, Schade U. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-α concentrations and outcome of patients with severe sepsis. Crit Care Med 1996;24:381-384.
43. 43. Brinkman BM, Zuijdeest D, Kaijzel EL, Breedveld FC, Verweij CL. Relevance of the tumor necrosis factor alpha (TNF α)-308 promoter polymorphism in TNF α gene regulation. J Inflamm 1995;46:32-41.
44. 44. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation. Proc Natl Acad Sci USA 1997;94:3195-3199.
45. 45. Han J, Brown T, Beutler B. Endotoxin-responsive sequences control cachectin/tumor necrosis factor biosynthesis at the translational level. J Exp Med 1990;171:465-475.
46. 46. Caput D, Beutler B, Hartog K, Thayer R, Brown-Shimer S, Cerami A. Identification of a common nucleotide sequence in the 3′-untranslated region of mRNA molecules specifying inflammatory mediators. Proc Natl Acad Sci USA 1986;83:1670-1674.
47. 47. Chen CY, Shyu AB, AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem Sci 1995;20:465-470.
48. 48. Jacob CO, Tashman NB. Disruption in the AU motif of the mouse TNF-α 3′ UTR correlates with reduced TNF production by macrophages in vitro. Nucleic Acids Res 1993;21:2761-2766.
49. 49. Beutler B, Brown T. Polymorphism of the mouse TNF-α locus: sequence studies of the 3′-untranslated region and first intron. Gene 1993:129:279-283.
50. 50. Jacob CO, Lee SK, Strassmann G. Mutational analysis of TNF-α gene reveals a regulatory role for the 3′-untranslated region in the genetic predisposition to lupus-lute autoimmune disease. J Immunol 1996;156:3043-3050.
51. 51. Lee JC, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994;372:739-746.
52. 52. Swantek JL, Cobb MH, Geppert TD. Jim N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor α (TNF-α) translation: glucocorticoids inhibit TNF-α translation by-blocking JNK/SAPK. Mol Cell Biol 1997:17:6274-6282.
53. 53. Han J, Thompson P, Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 1990;172:391-394.
54. 54. De Waal M, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174:1209-1220.
55. 55. Douni E, et al, Transgenic and knockout analyses of the role of TNF in immune regulation and disease pathogenesis. J Inflamm 1996;47:27-38.
56. 56. Miyazaki Y, et al. Expression of a tumor necrosis fattor-α transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis. J Clin Invest 1995;96:250-259.
57. 57. Kubota T, et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-α. Circ Res 1997;81:627-635.
58. 58. Wang E, Ma WJ, Aghajanian C, Spriggs DR. Posttranscriptional regulation of protein expression in human epithelial carcinoma cells by adenine uridine-rich elements in the 3′-untranslated region of tumor necrosis factor-α messenger RNA. Cancer Res 1997;57:5426-5433.
59. 59. Brown CR, Nakamura MS, Mosca JD, Hayward GS, Straus SE, Perera LP. Herpes simplex virus trans-regulatory protein ICP27 stabilizes and binds to 3′ ends of labile mRNA. J Virol 1995;69:7187-7195.
60. 60. Hel Z, Skamene E, Radzioth D. Two distinct regions in the 3′ untranslated region of tumor necrosis factor α mRNA form complexes with macrophage proteins. Mol Cell Biol 1996;16:5579-5590.
61. 61. Gueydan C, Honzet L, Marchant A, Sels A, Huez G, Kruys V. Engagement of tumor necrosis factor mRNA by an endotoxin-inducible cytoplasmic protein. Mol Med 1996;2:479-488.
62. 62. Carballo E, Lai WS, Blackshear PJ. Feedback inhibition of macrophage tumor necrosis factor-α production by tristetraprolin. Science 1998;281:1001-1005.
63. 63. Taylor GA, et al. A pathogenetic role for TNF α in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. Immunity 1996:4:445-454.
64. 64. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440:397-440.
65. 65. Stastny P. HLA-D and la antigens in rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum 1978;21:S139-S143
66. 66. Brunsberg U, et al. Expression of a transgenic class II Ab gene confers susceptibility to collagen-induced arthritis. Eur J Immunol 1994;24:1698-1702.
67. 67. Rosloniec EF, et al. An HLA-DR1 transgene confers susceptibility to collagen induced arthritis elicited with human type II collagen. J Exp Med 1997:185:1113-1122.
68. 68. Morefand LW, et al. Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum 1995:38:1581-1588.
69. 69. Olsen NJ, et al. A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group [published erratum appears in Arthritis Rheum 1996:39:1575]. Arthritis Rheum 1996;39:1102-1108.
70. 70. Goldschmidt TJ, Holmdahl R. Anti-T cell receptor antibody treatment of rats with established autologous collagen induced arthritis: suppression of arthritis without reduction of anti-type II collagen antoantibody levels. Eur J Immunol 1991;21:1327-1330.
71. 71. Chiocchia G, Boissier MC, Fournier C. Therapy against murine collagen-induced arthritis with T cell receptor V β-specific antibodies. Eur J Immunol 1991;21:2899-2905.
72. 72. Holmdahl R, Klareskog L, Rubin K, Larsson E, Wigzell H. T lymphocytes in collagen II-induced arthritis in mice. Characterization of arthritogenic collagen II-specific T-cell lines and clones, Scand J Immunol 1985;22:295-306.
73. 73. Tada Y, Ho A, Koh DR, Mak TW. Collagen-induced arthritis in CD4-or CD8-deficient mice: CD8+ T cells play a role in initiation and regulate recovery phase of collagen-induced arthritis. J Immunol 1996;156:4520-4526.
74. 74. Plows D, Kontogeorgos G, Kollias G. Mice lacking mature T and B lymphocytes develop arthritic lesions after immunization with type II collagen. J Immunol 1999;162:1018-1023.
75. 75. Mori L, Iselin S, De Libero G, Lesslauer W. Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type I (TNFR1) -IgG1 -treated and TNFR1-deficient mice. J Immunol 1996;157:3178-3182.
76. 76. Kuiper S, et al. Different roles of tumour necrosis factor α and interleukin 1 in murine streptococcal cell wall arthritis. Cytokine 1998;10:690-702.
77. 77. Probert L, Plows D, Kontogeorgos G, Kollias G. The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF transgenic mice. Eur J Immunol 1995;25:1794-1797.
78. 78. Alexopoulon L, Pasparakis M, Kollias G. A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling. Eur J Immunol 1997:27:2588-2592.
79. 79. Weiner HL. Oral tolerance for the treatment of autoimmune diseases, Annu Rev Med 1997;48:341-351.
80. 80. Katsikis PD, Chu CQ, Brennan FM, Maini RN, Feldmann M. Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med 1994:179:1517-1527.
81. 81. Miossec P, Naviliat M, Dupuy DA. Sany J. Banchereau J. Low levels of interleukin-4 and high levels of transforming growth factor β in rheumatoid synovitis. Arthritis Rheum 1990:33:1180-1187.
82. 82. Bessis N, et al, Modulation of proinflammatory cytokine production in tumour necrosis factor-α (TNF-α)-transgenic mice by treatment with cells engineered to secrete IL-4, IL-10 or IL-13. Clin Exp Immunol 1998;111:391-396.
83. 81. Geiler T, Kriegsmann J, Keyszer GM, Gay BE, Gay S. A new model for rheumatoid arthritis generated by engraftment of rheumatoid synovial tissue and normal human cartilage into SCTD mice. Arthritis Rheum 1994;37:1664-1671.
84. 84. Muller-Ladner U, et al. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol 1996;149:1607-1615.
85. 85. Butler DM, Piccoli DS, Hart PH, Hamilton JA. Stimulation of human synovial fibroblast DNA synthesis by recombinant human cytokines. J Rheumatol 1988;15:1463-1470.
86. 86. Dayer JM, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985;162:2163-2168.
87. 87. Rathanaswami P, Hachicha M, Wong WL, Schall TJ, McColl SR. Synergistic effect of interleukin-1 β and tumor necrosis factor α on interleukin-8 gene expression in synovial fibroblasts. Evidence that interleukin-8 is the major neutrophil activating chemokine released in response to monokine activation. Arthritis Rheum 1993;36:1295-1304.
88. 88. Firestein GS. Starving the synovium: angiogenesis and inflammation in rheumatoid arthritis. J Clin Invest 1999;103:3-4.
89. 89. Koch AE. Review: angiogenesis: implications for rheumatoid arthritis. Arthritis Rheum 1998;41:951-962.
90. 90. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin αν/β3 for angiogenesis. Science 1994;264:569-571.
91. 91. Storgard CM, Stupack DC, Jonczyk A, Goodman SL, Fox Rl, Cheresh DA. Decreased angiogenesis and arthritic disease in rabbits treated with an αν/β3 antagonist. J Clin Invest 1999;103:47-54.
92. 92. Neurath MF, et al. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol 1997;27:1743-1750.
93. 93. Powrie F, Leach MW, Mauze S, Menon S, Caddle LB, Coffman RL. Inhibition of Th 1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhigh CD4+ T cells. Immunity 1994;1:553-562.
94. 94. Watkins PE, Warren BF, Stephens S, Ward P, Foulkes R. Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor α. Gut 1997;40:628-633.
95. 95. Targan SR, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-1035.
96. 96. Podolsky DK. Inflammatory bowel disease ( I ). N Engl J Med 1991;325:928-937.
97. 97. Strober W, Fuss IJ, Ehrhardt RO, Neurath M, Boirivant M, Ludviksson BR. Mucosal immunoregulation and inflammatory bowel disease: new insights from murine models of inflammation. Scand J Immunol 1998;48:453-458.
98. 98. Van Deventer SJ. Tumour necrosis factor and Crohn's disease. Gut 1997;40:443-448.
99. 99. Kaiser GC, Polk DB. Tumor necrosis factor α regulates proliferation in a mouse intestinal cell line. Gastroenterology 1997;112:1231-1240.
100. 100. Heyman M, et al. Mononuclear cells from infants allergic to cow's milk secrete tumor necrosis factor α, altering intestinal function. Gastroenterology 1994;106:1514-1523.
101. 101. Pender SL, Fell JM, Chamow SM, Ashkenazi A, MacDonald TT, A p55 TNF receptor immunoadhesin prevents T cell mediated intestinal injury by inhibiting matrix metalloproteinase production. J Immunol 1998;160:4098-4103.
102. 102. Flory CM, Jones ML, Miller BF, Warren JS. Regulatory roles of tumor necrosis factor-α and interleukin-l β in monocyte chemoattractant protein-1-mediated pulmonary granuloma formation in the rat. Am J Pathol 1995;146:450-462.
103. 103. Sankey EA, et al. Early mucosal changes in Crohn's disease. Gut 1993;34:375-381.
104. 104. Rudin W, et al. Resistance to cerebral malaria in tumor necrosis factor-α/β-deficient mice is associated with a reduction of intercellular adhesion molecule-1 up-regulation and T helper type 1 response. Am J Pathol 1997;150:257-266.
105. 105. Zhan Y, Cheers C. Control of IL-12 and IFN-γ production in response to live or dead bacteria by TNF and other factors. J Immunol 1998;161:1447-1453.
106. 106. Mencacci A, et al. Defective co-stimulation and impaired Th 1 development in tumor necrosis factor/lymphotoxin α double-deficient mice infected with Candida albicans. Int Immunol 1998;10:37-48.
107. 107. Shibuya K, et al. IL-1 α and TNF-α are required for IL-12-induced development of Th1 cells producing high levels of IFN-γ in BALB/c but not C57BL/6 mice. J Immunol 1998;160:1708-1716.
108. 108. Becher B, Blain M, Giacomini PS, Antel JP. Inhibition of Th1 polarization by soluble TNF receptor is dependent on antigen-presenting cell-derived IL-12. J Immunol 1999;162:684-688.
109. 109. Sirober W, et al. Reciprocal IFN-γ and TGF-β responses regulate the occurrence of mucosal inflammation. Immunol Today 1997;18:61-64.
110. 110. Plevy SE, et al. A role for TNF-α and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol 1997;159:6276-6282.
111. 111. Sieber G, Herrmann F, Zeitz M, Teichmann H, Ruhl H. Abnormalities of B-cell activation and immunoregulation in patients with Crohn's disease. Gut 1984;25:1255-1261.
112. 112. Shanahan F. Antibody 'markers' in Crohn's disease: opportunity or overstatement? Gut 1997;40:557-558.
113. 113. Poussier P, Edouard P, Lee C, Binnie M. Julius M. Thymus-independent development and negative selection of T cells expressing T cell receptor α/β in the intestinal epithelium: evidence for distinct circulation patterns of gut-and thymus-derived T lymphocytes. J Exp Med 1992:176:187-199.
114. 114. Sharief MK, Hentges R. Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis. N Engl J Med 1991;325:467-472.
115. 115. Hofman FM, Hinton DR, Johnson K, Merrill JE. Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 1989;170:607-612.
116. 116. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 1994;84:2068-2101.
117. 117. Philip R, Epstein LB. Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, γ-interferon and interleukin-1. Nature 1986;323:86-89.
118. 118. Ruddle NH, et al. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med 1990;172:1193-1200.
119. 119. Baker D, Butler D, Scallon BJ, O'Neill JK, Turk JL, Feldmann M. Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur J Immunol 1994;24:2040-2048.
120. 120. Hafler DA, Weiner HL. MS: a CNS and systemic autoimmune disease. Immunol Today 1989:10:104-107.
121. 121. Hillert J, Olerup O. Multiple sclerosis is associated with genes within or close to the HLA-DR-DQ subregion on a normal DRI5,DQ6,Dw2 haplotype. Neurology 1993;43:163-168.
122. 122. Paterson PY. Transfer of allergic encephalomyelitis in rats by means of lymph mode cells. J Exp Med 1960;111:119-136.
123. 123. Ben-Nun A, Wekerle H, Cohen IR. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol 1981;11:195-199.
124. 124. Rodriguez M, Pavelko KD, Njenga MK, Logan WC, Wettstein PJ. The balance between persistent virus infection and immune cells determines demyelination. J Immunol 1996;157:5699-5709.
125. 125. Rivera-Quinones C, McGavern D, Schmelzer JD, Hunter SF, Low PA, Rodriguez M. Absence of neurological deficits following extensive demyelination in a class I-deficient murine model of multiple sclerosis. Nat Med 1998;4:187-193.
126. 126. Schluesener HJ, Wekerle H. Autoaggressive T lymphocyte lines recognizing the encephalitogenic region of myelin basic protein: in vitro selection from unprimed rat T lymphocyte populations. J Immunol 1985;135:3128-3133.
127. 127. Tournier-Lasserve E, Hashim GA, Bach MA. Human T-cell response to myelin basic protein in multiple sclerosis patients and healthy subjects. J Neurosci Res 1988;19:149-156.
128. 128. Moalem G, Leibowitz-Amit R, Yoles E, Mor F, Cohen IR, Schwarte M. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med 1999;5:49-55.
129. 129. Kerschensteiner M, et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 1999;189:865-870.
130. 130. Kassiotis G, Bauer J, Akassoglou K, Lassmann H, Kollias G, Probert L. A tumor necrosis factor-induced model of human primary demyelinating diseases develops in immunodeficient mice. Eur J Immunol 1999;29:912-917.
131. 131. Mendel I, Kerlero DR, Ben-Nun A. A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor V β expression of encephalitogenic T cells. Eur J Immunol 1995;25:1951-1959.
132. 132. Korner H, Riminton DS, Strickland DH, Lemckert FA, Pollard JD, Sedgwick JD. Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting. J Exp Med 1997;186:1585-1590.
133. 133. Lin J, et al. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med 1998;4:78-83.
134. 134. Suen WE, Bergman CM, Hjelmstrom P, Ruddle NH. A critical role lor lymphotoxin in experimental allergic encephalomyelitis. J Exp Med 1997;186:1233-1240.
135. 135. Sean RD, Korner H, Strickland DH, Lemckert FA, Pollard JD, Sedgwick JD. Challenging cytokine redundancy: inflammatory cell movement and clinical course of experimental autoimmune encephalomyelitis are normal in lymphotoxin-deficient, but not tumor necrosis factor-deficient, mice. J Exp Med 1998;187:1517-1528.
136. 136. Eugster HP, Frei K, Bachmann R, Bleuthmann H, Lassmann H, Fontana A. Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1. Eur J Immunol 1999;29:626-632.
137. 137. Frei K, Eugster HP, Bopst M, Constantinescu CS, Lavi E, Fomana A. Tumor necrosis factor α and lymphotoxin α are not required for induction of acute experimental autoimmune encephalomyelitis. J Exp Med 1997;185:2177-2182.
138. 138. Kassiotis G, Pasparakis M, Kollias G, Probert L. TNF accelerates the onset but does not alter the incidence and severity of myelin basic protein-induced experimental autoimmune encephalomyelitis. Eur J Immunol 1999;29:774-780.
139. 139. Peschon JJ, et al. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 1998;160:943-952.
140. 140. Matsurnoto M, Mariathasan S, Nahm MH, Baranyay F, Peschon JJ, Chaplin DD. Role of lymphotoxin and the type 1 TNF receptor in the formation of germinal centers. Science 1996;271: 1289-1291.
141. 141. Shaw MK, Kim C, I Hao HW, Chen F, Tse HY. Induction of myelin basic protein-specific experimental autoimmune encephalomyelitis in C57BL/6 mice: mapping of T cell epitopes and T cell receptor V β gene segment usage. J Neurosci Res 1996i;45:690-699.
142. 142. Fritz RB, Kalvakolanu I, Thymic expression of the golli-myclin basic protein gene in the SJL/J mouse. J Neuroimmunol 1995;57:93-99.
143. 143. Harrington CJ, et al. Dillerential tolerance is induced in T cells recognizing distinct epitopes of myelin basic protein. Immunity 1998;8:571-580.
144. 144. Targoni OS, Lehmann PV. Endogenous myelin basic protein inactivates the high avidity T cell repertoire. J Exp Med 1998;187:2055-2063.
145. 145. Van Oosten BW, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996;47:1531-1534.
146. 146. Arnason BGW. International workshop on Th1/Th2: T-cell differentiation in MS and autoimmunity; 1998 Apr 1-5; Savannah (GA).
147. 147. Llewellyn Smith N, Lai M, Miller DH, Rudge P, Thompson AJ, Cuzner ML. Effects of anti-CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor α production: a study of 29 multiple sclerosis patients entered into a clinical trial of CM-T412. Neurology 1997;48:810-816.
148. 148. Aggarwal BB, Natarajan K. Tumor necrosis factors: developments during the last decade. Eur Cytokine Netw 1996;7:93-124.
149. 149. Aderka D. The potential biological and clinical signifieance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev 1996:7:231-240.
150. 150. Yuan J. Transducing signals of life and death. Curr Opin Cell Biol 1997;9:247-251.
151. 151. Rothe J, et al. Mice lacking the tumour necrosis factor receptor I are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 1993;364:798-802.
152. 152. Pfeffer K, et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 1993;73:457-467.
153. 153. Nashleanas M, Kanaly S, Scott P. Control of Leishmania major infection in mice lacking TNF receptors. J Immunol 1998;160:5506-5513.
154. 154. Ruby J, Bluethmann H, Peschon JJ. Antiviral activity of tumor necrosis factor (TNF) is mediated via p55 and p75 TNF receptors. J Exp Med 1997;186:1591-1596.
155. 155. Erickson SL, et al. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 1994;372:560-563.
156. 156. Tartaglia LA, Pennica D, Goeddel DV. Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J Biol Chem 1993;268:18542-18548.
157. 157. Lucas R, et al. Crucial role of tumor necrosis factor (TNF) receptor 2 and membrane-bound TNF in experimental cerebral malaria. Eur J Immunol 1997;27:1719-1725.
158. 158. Kusters S, et al. In vivo evidence for a functional role of both tumor necrosis factor (TNF) receptors and transmembrane TNF in experimental hepatitis. Eur J Immunol 1997;27:2870-2875.
159. 159. Wang B, et al. Depressed Langerhans cell migration and reduced contact hypersensitivity response in mice lacking TNF receptor p75. J Immunol 1997;159:6148-6155.
160. 160. Tartaglia LA, Weber RF, Figari IS, Reynolds C, Palladino MAJ, Goeddel DV. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci USA 1991;88:9292-9196.
161. 161. Slowik MR, De Luca LG, Fiers W, Pober JS. Tumor necrosis factor activates human endothelial cells through the p55 tumor necrosis factor receptor but the p75 receptor contributes to activation at low tumor necrosis factor concentration Am J Pathol 1993;143:1724-1730.
162. 162. Santee SM, Owen-Schaub LB. Human tumor necrosis factor receptor p75/80 (CD120b) gene, structure and promoter characterization. J Biol Chem 1996;271:21151-21159.
163. 163. Grell M, Wajant H, Zimmermann G, Scheurich P. The type l receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci USA 1998;95:570-575.
164. 164. Douni E, Kollias G. A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin α, or the p55TNF-R. J Exp Med 1998;188:1343-1352.
165. 165. Hober D, et al. High plasma level of soluble tumor necrosis factor receptor type II (sTNFRII) in asymptomatic HIV-1 -infected patients. Infection 1996;24:213-217.
166. 166. Schroder J, Stuber F, Gallati H, Schade FU, Kremer B. Pattern ot soluble TNF receptors I and II in sepsis. Infection 1995;23:143-148.
167. 167. Diez-Ruiz A, Tilz GP, Zangerle R, Baier Bitterlich G, Wachter H, Fuchs D. Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol 1995; 54:1-8.
168. 168. Wallgren A. Festin R, Gidlof C, Dohlsten M, Kalland T, Totterman TH. Efficient killing of chronic B-lymphocytic leukemia cells by superantigen-directed T cells. Blood 1993;82:1230-1238.
169. 169. Murphy K, Haudek SB, Thompson M, Giroir BP. Molecular biology of septic shock. New Horiz 1998;6:181-193.
170. 170. Reinhard C, Shamoon B, Shyamala V, Williams LT. Tumor necrosis factor α-induced activation of c-jun N-terminal kinase is mediated by TRAF2. EMBO J 1997;16:1080-1092.
171. 171. Yeh WC, et al. Early lethality, functional NF-κB activation, and increased sensitivity to TNF-induced cell death in TRAF2 deficient mice. Immunity 1997;7:715-725.
172. 172. Weih F, Durham SK, Barton DS, Sha WC, Baltimore D, Bravo R. p50-NF-κB complexes partially compensate for the absence of ReLB: severely increased pathology in p50-′ relB-′ double-knockout mice. J Exp Med 1997;185:1359-1370.
173. 173. Bohrer H, et al. Role of NFκB in the mortality of sepsis. J Clin Invest 1997;100:972-985.
174. 174. Marinos G, et al. Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection. Gastroentcrology 1995;108:1453-1463.
175. 175. Lucas R, Lou J, Morel DR, Ricou B, Suter PM, Grau GE. TNF receptors in Ihe microvascular pathology of acute respiratory distress syndrome and cerebral malaria. J Leukoc Biol 1997;61:551-558.
176. 163. Grell M, Wajant H, Zimmermann G, Scheurich P. The type l receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci USA 1998;95:570-575.
177. 164. Douni E, Kollias G. A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin α, or the p55TNF-R. J Exp Med 1998;188:1343-1352.
178. 165. Hober D, et al. High plasma level of soluble tumor necrosis factor receptor type II (sTNFRII) in asymptomatic HIV-1 -infected patients. Infection 1996;24:213-217.
179. 166. Schroder J, Stuber F, Gallati H, Schade FU, Kremer B. Pattern ot soluble TNF receptors I and II in sepsis. Infection 1995;23:143-148.
180. 167. Diez-Ruiz A, Tilz GP, Zangerle R, Baier Bitterlich G, Wachter H, Fuchs D. Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol 1995; 54:1-8.
181. 168. Wallgren A. Festin R, Gidlof C, Dohlsten M, Kalland T, Totterman TH. Efficient killing of chronic B-lymphocytic leukemia cells by superantigen-directed T cells. Blood 1993;82:1230-1238.
182. 169. Murphy K, Haudek SB, Thompson M, Giroir BP. Molecular biology of septic shock. New Horiz 1998;6:181-193.
183. 170. Reinhard C, Shamoon B, Shyamala V, Williams LT. Tumor necrosis factor α-induced activation of c-jun N-terminal kinase is mediated by TRAF2. EMBO J 1997;16:1080-1092.
184. 171. Yeh WC, et al. Early lethality, functional NF-κB activation, and increased sensitivity to TNF-induced cell death in TRAF2 deficient mice. Immunity 1997;7:715-725.
185. 172. Weih F, Durham SK, Barton DS, Sha WC, Baltimore D, Bravo R. p50-NF-κB complexes partially compensate for the absence of ReLB: severely increased pathology in p50-′ relB-′ double-knockout mice. J Exp Med 1997;185:1359-1370.
186. 173. Bohrer H, et al. Role of NFκB in the mortality of sepsis. J Clin Invest 1997;100:972-985.
187. 174. Marinos G, et al. Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection. Gastroentcrology 1995;108:1453-1463.
188. 175. Lucas R, Lou J, Morel DR, Ricou B, Suter PM, Grau GE. TNF receptors in Ihe microvascular pathology of acute respiratory distress syndrome and cerebral malaria. J Leukoc Biol 1997;61:551-558.
189. 176. De Beaux AC, Goldie AS, Ross JA, Carter DC, Fearon KC. Serum concentrations of inflammatory mediators related to organ failure in patients with acute pancreatitis. Br J Surg 1996;83:349-353.
190. 177. Gabay C, et al. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus crythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 1997;24:303-308.
191. 178. Cope AP, et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 1992;35:1160-1169.
192. 179. Aderka D, et al. Shedding kinetics of soluble tumor necrosis factor (TNF) receptors after systemic TNF leaking during isolated limb perfusion. Relevance to the pathophysiology of septic shock. J Clin Invest 1998;101:650-659.
193. 180. De Kossodo S, Critico B, Grau GE. Modulation of the transcripts for tumor necrosis factor-α and its receptors in vivo. Eur J Immunol 1994;24:769-772.
194. 181. Rothe M, Sarma V, Dixit VM, Goeddel DV. TRAFZ-mediated activation of NF-κ B by TNF receptor 2 and CD40. Science 1995;269:1424-1427.
195. 182. Rao P, Hsu KC, Chao MV. Upregulation of NF-κ B-dependent gene expression mediated by the p75 tumor necrosis factor receptor. J Interferon Cytokine Res 1995;15:171-177.
196. 183. Boldin MP, et al. Self-association of the "death domains" of the p55 tumor necrosis factor (TNF) receptor and Fas/APO1 prompts signaling for TNF and Fas/APO1 effets. J Biol Chem 1995;270:387-391.
197. 184. Cheng G, Baltimore D. TANK, a co-inducer with TRAF2 of TNF-and CD 40L-mediated NF-κB activation. Genes Dev 1996:10:963-973.
198. 185. Rabizadeh S, et al. Induction of apoptosis by the low-affinity NGF receptor. Science 1993;261:345-348.
199. 186. Grau GE, Maennel DN. TNF inhibition and sepsis - sounding a cautionary note. NatMed 1997;3:1193-1195.
200. 187. Fisher CJJ, et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996:334:1697-1702.
201. 188. Kallinowski B, et al. Induction of tumour necrosis factor (TNF) receptor type p.55 and p75 in patients with chronic hepatitis C virus (HCV) infection. Clin Exp Immunol 1998;111:269-277.
202. 189. Butler DM, et al. DBA/1 mice expressing the human TNF-α transgene develop a severe, erosive arthritis: characterization of the cytokine cascade and cellular composition. J Immunol 1997:159:2867-2876.
203. 190. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 1986;319:516-518.
204. 191. Saklatvala J. Tumour necrosis factor α stimulus resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1986;322:547-549.
205. 192. Taupin V, Renno T, Bourbonniere L, Peterson AC, Rodriguez M, Owens T. Increased severity of experimental autoimmune encephalomyelitis, chronic macrophage/microglial reactivity, and demyelination in transgenic mice producing tumor necrosis factor-α in the central nervous system. Eur J Immunol 1997;27:905-913.
206. 193. Jacob CO, Aiso S, Michie SA, McDevitt HO, Acha-Orbea H. Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): similarities between TNF-α and interleukin I. Proc Natl Acad Sci USA 1990;87:968-972.
207. 194. McSorley SJ, et al. Immunological tolerance to a pancreatic antigen as a result of local expression of TNFα by islet β cells. Immunity 1997;7:401-409.
208. 195. Fujimura T, et al. Dissection of the effects of tumor necrosis factor-α and class II gene polymorphisms within the MHC on murine systemic lupus erythematosus (SLE). Int Immunul 1998;10:1467-1472.
209. 196. Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice J Exp Med 1994;179:305-310.
210. 197. Gordon C, Ranges GE, Greenspan JS, Wofsy D. Chronic therapy with recombinant tumor necrosis factor-α in autoimmune NZB/NZW F1 mice. Clin Immunol Immunopathol 1989;52:421-434.
211. 198. Zhou T, Edwards CK, Yang P, Wang Z, Bluethmann H, Mountz JD. Greatly accelerated lymphadenopathy and autoimmune disease in lpr mice lacking tumor necrosis factor receptor l. J Immunol 1996;156:2661-2665.